AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

DEVELOPMENTS

1 Drugs in Development

1 Drugs in Development

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

API

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

1DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: 2159103-66-7, Navocaftor [inn], Navocaftor [usan], Glpg3067, Abbv-3067, Unii-w2f2xu189o

Molecular Formula

C₁₅H₁₁F₃N₄O₅S

Molecular Weight

416.3 g/mol

InChI Key

WOXOLLSAICIZNO-UHFFFAOYSA-N

FDA UNII

W2F2XU189O

1 2D Structure

Navocaftor

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

[5-[3-amino-5-[4-(trifluoromethoxy)phenyl]sulfonylpyridin-2-yl]-1,3,4-oxadiazol-2-yl]methanol

2.1.2 InChI

InChI=1S/C15H11F3N4O5S/c16-15(17,18)27-8-1-3-9(4-2-8)28(24,25)10-5-11(19)13(20-6-10)14-22-21-12(7-23)26-14/h1-6,23H,7,19H2

2.1.3 InChI Key

WOXOLLSAICIZNO-UHFFFAOYSA-N

2.1.4 Canonical SMILES

C1=CC(=CC=C1OC(F)(F)F)S(=O)(=O)C2=CC(=C(N=C2)C3=NN=C(O3)CO)N

2.2 Other Identifiers

2.2.1 UNII

W2F2XU189O

2.3 Synonyms

2.3.1 Depositor-Supplied Synonyms

1. 2159103-66-7

2. Navocaftor [inn]

3. Navocaftor [usan]

4. Glpg3067

5. Abbv-3067

6. Unii-w2f2xu189o

7. W2f2xu189o

8. Navocaftor [usan:inn]

9. Glpg-3067

10. Who 11090

11. 1,3,4-oxadiazole-2-methanol, 5-(3-amino-5-((4-(trifluoromethoxy)phenyl)sulfonyl)-2-pyridinyl)-

12. (5-(3-amino-5-((4-(trifluoromethoxy)phenyl)sulfonyl)pyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanol

13. [5-[3-amino-5-[4-(trifluoromethoxy)phenyl]sulfonylpyridin-2-yl]-1,3,4-oxadiazol-2-yl]methanol

14. Chembl4802150

15. Schembl19666838

16. Woxollsaicizno-uhfffaoysa-n

17. Akos040757366

18. Da-56020

19. Ms-27234

20. Hy-109152

21. Cs-0116061

22. G18325

2.4 Create Date

2018-01-29

3 Chemical and Physical Properties

Molecular Formula	C₁₅H₁₁F₃N₄O₅S
Molecular Weight	416.3 g/mol
XLogP3	0.8
Hydrogen Bond Donor Count	2
Hydrogen Bond Acceptor Count	12
Rotatable Bond Count	5
Exact Mass	g/mol
Monoisotopic Mass	g/mol
Topological Polar Surface Area	150
Heavy Atom Count	28
Formal Charge	0
Complexity	624
Isotope Atom Count	0
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1